Tags

Type your tag names separated by a space and hit enter

Lixisenatide plus basal insulin in patients with type 2 diabetes mellitus: a meta-analysis.
J Diabetes Complications. 2014 Nov-Dec; 28(6):880-6.JD

Abstract

AIMS

The efficacy of the once-daily prandial GLP-1 receptor agonist lixisenatide plus basal insulin in T2DM was assessed by pooling results of phase III trials.

METHODS

A meta-analysis was performed of results from three trials in the GetGoal clinical program concerning lixisenatide or placebo plus basal insulin with/without OADs. The primary endpoint was change in HbA1c from baseline to week 24. Secondary endpoints were change in PPG, FPG, insulin dose, and weight from baseline to week 24. Hypoglycemia rates and several composite endpoints were assessed.

RESULTS

Lixisenatide plus basal insulin was significantly more effective than basal insulin alone at reducing HbA1c at 24 weeks. Composite and secondary endpoints were improved significantly with lixisenatide plus basal insulin, with the exception of FPG, which showed no significant difference between the groups. Lixisenatide plus basal insulin was associated with an increased incidence of hypoglycemia versus basal insulin alone.

CONCLUSIONS

Lixisenatide plus basal insulin resulted in significant improvement in glycemic control versus basal insulin alone, particularly in terms of controlling PPG. Prandial lixisenatide in combination with basal insulin is a suitable option for treatment intensification in patients with T2DM insufficiently controlled with basal insulin, as these agents have complementary effects on PPG and FPG, respectively.

Authors+Show Affiliations

Centre Hospitalier Universitaire de Nantes, Nantes, France. Electronic address: Bernard.charbonnel@univ-nantes.fr.Sanofi, Paris, France.CIBER de Fisiopatalogía de la Obesidad y Nutrición (CIBEROBN), Insituto de Salud Carlos III, and Hospital Virgen de la Victoria, Malaga, Spain.Hospital Universitari Germans Trias i Pujol, Barcelona, Spain.Diabetes Research Centre, University of Leicester, Leicester, UK.

Pub Type(s)

Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

25130920

Citation

Charbonnel, Bernard, et al. "Lixisenatide Plus Basal Insulin in Patients With Type 2 Diabetes Mellitus: a Meta-analysis." Journal of Diabetes and Its Complications, vol. 28, no. 6, 2014, pp. 880-6.
Charbonnel B, Bertolini M, Tinahones FJ, et al. Lixisenatide plus basal insulin in patients with type 2 diabetes mellitus: a meta-analysis. J Diabetes Complicat. 2014;28(6):880-6.
Charbonnel, B., Bertolini, M., Tinahones, F. J., Domingo, M. P., & Davies, M. (2014). Lixisenatide plus basal insulin in patients with type 2 diabetes mellitus: a meta-analysis. Journal of Diabetes and Its Complications, 28(6), 880-6. https://doi.org/10.1016/j.jdiacomp.2014.07.007
Charbonnel B, et al. Lixisenatide Plus Basal Insulin in Patients With Type 2 Diabetes Mellitus: a Meta-analysis. J Diabetes Complicat. 2014 Nov-Dec;28(6):880-6. PubMed PMID: 25130920.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Lixisenatide plus basal insulin in patients with type 2 diabetes mellitus: a meta-analysis. AU - Charbonnel,Bernard, AU - Bertolini,Monica, AU - Tinahones,Francisco J, AU - Domingo,Manuel Puig, AU - Davies,Melanie, Y1 - 2014/07/18/ PY - 2014/05/28/received PY - 2014/07/14/revised PY - 2014/07/14/accepted PY - 2014/8/19/entrez PY - 2014/8/19/pubmed PY - 2015/8/25/medline KW - Basal insulin KW - Combination KW - Lixisenatide KW - Meta-analysis KW - Prandial SP - 880 EP - 6 JF - Journal of diabetes and its complications JO - J. Diabetes Complicat. VL - 28 IS - 6 N2 - AIMS: The efficacy of the once-daily prandial GLP-1 receptor agonist lixisenatide plus basal insulin in T2DM was assessed by pooling results of phase III trials. METHODS: A meta-analysis was performed of results from three trials in the GetGoal clinical program concerning lixisenatide or placebo plus basal insulin with/without OADs. The primary endpoint was change in HbA1c from baseline to week 24. Secondary endpoints were change in PPG, FPG, insulin dose, and weight from baseline to week 24. Hypoglycemia rates and several composite endpoints were assessed. RESULTS: Lixisenatide plus basal insulin was significantly more effective than basal insulin alone at reducing HbA1c at 24 weeks. Composite and secondary endpoints were improved significantly with lixisenatide plus basal insulin, with the exception of FPG, which showed no significant difference between the groups. Lixisenatide plus basal insulin was associated with an increased incidence of hypoglycemia versus basal insulin alone. CONCLUSIONS: Lixisenatide plus basal insulin resulted in significant improvement in glycemic control versus basal insulin alone, particularly in terms of controlling PPG. Prandial lixisenatide in combination with basal insulin is a suitable option for treatment intensification in patients with T2DM insufficiently controlled with basal insulin, as these agents have complementary effects on PPG and FPG, respectively. SN - 1873-460X UR - https://www.unboundmedicine.com/medline/citation/25130920/Lixisenatide_plus_basal_insulin_in_patients_with_type_2_diabetes_mellitus:_a_meta_analysis_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1056-8727(14)00207-4 DB - PRIME DP - Unbound Medicine ER -